Nonsteroidal anti-inflammatory drugs and risk of digestive cancers at sites other than the large bowel

Cancer Epidemiology Biomarkers and Prevention

Volumn 9, Issue 1, 2000, Pages 119-123

  Coogan, Patricia F ^a   Rosenberg, Lynn ^a   Palmer, Julie R ^a   Strom, Brian L ^b   Zauber, Ann G ^c   Stolley, Paul D ^d   Shapiro, Samuel ^a  

^a BOSTON UNIVERSITY   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; DIGESTIVE SYSTEM CANCER; DRUG EFFECT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CONFIDENCE INTERVALS; DATABASES; DIGESTIVE SYSTEM NEOPLASMS; ESOPHAGEAL NEOPLASMS; FEMALE; GALLBLADDER NEOPLASMS; HUMANS; INTESTINAL NEOPLASMS; INTESTINE, LARGE; LIVER NEOPLASMS; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; PANCREATIC NEOPLASMS; RISK FACTORS; STOMACH NEOPLASMS;

EID: 0033968548     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Rosenberg, L., Palmer, J. R., Zauber, A. G., Warshauer, M. E., Stolley, P. D., and Shapiro, S. A hypothesis: nonsteroidal anti-inflammatory drugs reduce the incidence of large bowel cancer. J. Natl. Cancer Inst., 83: 355-358, 1991.
2. Rosenberg, L., Louik, C., and Shapiro, S. Nonsteroidal anti-inflammatory drug use and reduced risk of large bowel carcinoma. Cancer (Phila.), 82: 2326-2333, 1998.
3. Giovannucci, E., Rim, E. B., Stampfer, M. J., Colditz, G. A., Ascherio, A., and Willett, W. C. Aspirin use and the risk of colorectal cancer and adenoma in male health professionals. Ann. Intern. Med., 121: 241-246, 1994.
4. Giovannucci, E., Egan, K., Hunter, D. J., Stampfer, M. J., Colditz, G. A., Ascherio, A., Willett, W. C., and Speizer, F. E. Aspirin and the risk of colorectal cancer in women. N. Engl. J. Med., 333: 609-614, 1995.
5. Berkel, H. J., Holcombe, R. F., Middlebrooks, M., and Kannan, K. Non-steroidal antiinflammatory drugs and colorectal cancer. Epidemiol. Rev., 18: 205-217, 1996.
6. Thun, M. J., Namboodiri, M. M., and Heath, C. W., Jr. Aspirin use and reduced risk of fatal colon cancer. N. Engl. J. Med., 325: 1593-1596, 1991.
7. Muscat, J. E., Stellman, S. D., and Wynder, E. L. Nonsteroidal antiinflamma-tory drugs and colorectal cancer. Cancer (Phila.), 74: 1847-1854, 1994.
8. Kudo, T., Narisawa, T., and Abo, S. Antitumor activity of indomethacin on methylazoxymethanol-induced large bowel tumors in rats. Gann, 71: 260-264, 1980.
9. Pollard, M., and Luckert, P. H. Indomethacin treatment of rats with dimethylhydrazine-induced intestinal tumors. Cancer Treat. Rep., 64: 1323-1327, 1980.
10. Pollard, M., and Luckert, P. H. Effect of piroxicam on primary intestinal tumors induced in rats by N-methylnitrosourea. Cancer Lett., 25: 117-121, 1984.
11. Metzger, U., Meier, J., Uhlshmid, G., and Weihe, H. Influence of various prostaglandin synthesis inhibitors on DMH-induced rat colon cancer. Dis. Colon Rectum. 27: 366-369, 1984.
12. Reddy, B. S., Maruyama, H., and Kelloff, G. Dose-related inhibition of dietary piroxicam, a nonsteroidal anti-inflammatory drug, during different stages of rat colon tumor development. Cancer Res., 47: 5340-5346, 1987.
13. Reddy, B. S., Nayini, J., Tokumo, K., Rigotty, J., Zang, E., and Kelloff, G. Chemoprevention of colon carcinogenesis by concurrent administration of piroxicam, a nonsteroidal anti-inflammatory drug with D,L-α-difluoromethylornithine, an ornithine decarboxylase inhibitor, in diet. Cancer Res., 50: 2562-2568, 1990.
14. Rubio, C. A. Antitumoral activity of indomethacin on experimental esophageal tumors. J. Natl. Cancer Inst., 705-707, 1984.
15. Rubio, C. A. Further studies on the therapeutic effect of indomethacin on experimental esophageal tumours. Cancer (Phila.), 58: 1029-1031, 1986.
16. Takahashi, M., Furukawa, F., Toyoda, K., Sato, H., Hasegawa, R., Imaida, K., and Hayashi, Y. Effects of various prostaglandin synthesis inhibitors on pancreatic carcinogenesis in hamsters after initiation with N-nitrosobis(2-oxopropyl)amine. Carcinogenesis (Lond.), 11: 393-395, 1990.
17. Tanaka, T., Kojima, T., Okumura, A., Sugie, S., and Mori, H. Inhibitory effect of the non-steroidal anti-inflammatory drugs, indomethacin and piroxicam on 2-acetylaminofluorene-induced hepatocarcinogenesis in male ACI/N rats. Cancer Lett., 68: 111-118, 1993.
18. Jalbert, G., and Castonguay, A. Effects of NSAIDs on NNK-induced pulmonary and gastric tumorigenesis in A/J mice. Cancer Lett., 66: 21-28, 1992.
19. Thun, M. S., Namboodiri, M. M., Calle, E. E., Flanders, M. D., and Heath, C. W., Jr. Aspirin use and risk of fatal cancer. Cancer Res., 53: 1322-1327, 1993.
20. Gridley, G., McLaughlin, J. K., Ekbom, A., Klareskog, L., Adami, H. O., Hacker, D. G., Hoover, R., and Fraumeni, J. F. Incidence of cancer among patients with rheumatoid arthritis. J. Natl. Cancer Inst., 85: 307-311, 1993.
21. Funkhouser, E. M., and Sharp, G. B. Aspirin and reduced risk of esophageal carcinoma. Cancer (Phila.), 76; 1116-1119, 1995.
22. Farrow, D. C., Vaughan, T. L., Hansten, P. D., Stanford, J. L., Risch, H. A., Gammon, M. D., Chow, W. H., Dubrow, R., Ahsan, H., Mayne, S. T., Schoenherg, J. B., West, A. B., Rotterdam, H., Fraumeni, J. F., Jr., and Blot, W. J. Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol. Biomark. Prev., 7: 97-102, 1998.
23. Shapiro, S. Case-control surveillance. In: B. L. Strom (ed.), Pharmacoepidemiology, Ed. 2, pp.301-322. Chichester, United Kingdom: John Wiley and Sons, 1994.
24. Schlesselman, J. J. Case-Control Studies: Design, Conduct, Analysis. New York: Oxford University Press, 1982.
25. Schreinemachers, D. M., and Everson, R. B. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology, 5: 138-146, 1994.
26. Taketo, M. M. Cyclooxygenase-2 inhibitors in tumorigenesis (Part 1). J. Natl. Cancer Inst., 90: 1529-1536, 1998.
27. Botha, J. H., Robinson, K. M., Ramchurren, N., Reddi, K., and Norman, R. J. Human esophageal carcinoma cell lines: prostaglandin production, biological properties, and behavior in nude mice. J. Natl. Cancer Inst., 76: 1053-1056, 1986.
28. Taketo, M. M. Cyclooxygenase-2 inhibitors in tumorigenesis (Part II). J. Natl. Cancer Inst., 90: 1609-1620, 1998.
29. Vainio, H., and Morgan, G. Non-steroidal anti-inflammatory drugs and the chemoprevention of gastrointestinal cancers. Scand. J. Gastroenterol., 33: 785-789, 1998.
30. Bennet, A., and Del Tacca, M. Proceedings: prostaglandins and human colonic cancer. Gut, 16: 409, 1975.
31. Murata, H., Kawano, S., Tsuji, S., Tsuji, M., Sawaoka, H., Kimura, Y., Schiozaki, H., and Hori, M. Cyclooxygenase-2 overexpression enhances lymphatic invasion and metastasis in human gastric carcinoma. Am. J. Gastroenterol., 94: 451-455, 1999.
32. Ratnasinghe, D., Tangrea, J. A., Roth, M. J., Dawsey, S. M., Anver, M., Kasprzak, B. A., Hu, N., Wang, Q. H., and Taylor, P. R. Expression of cyclooxygenase-2 in human adenocarcinomas of the gastric cardia and corpus. Oncol. Rep., 6: 965-968, 1999.
33. Shiota, G., Okubo, M., Noumi, T., Noguchi, N., Oyama, K., Takano, Y., Yashima, K., Kishimoto, Y., and Kawasaki, H. Cyclooxygenase-2 expression in hepatocellular carcinoma. Hepato-Gastroenlerol., 46: 407-412, 1999.
34. Zimmerman, K. C., Sarbia, M., Weber, A. A., Borchard, F., Gabbert, H. E., and Schror, K. Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res., 159: 198-204, 1999.
35. Sawaoka, H., Kawano, S., Tsuji, S., Tsjui, M., Murata, H., and Hori, M. Effects of NSAIDs on proliferation of gastric cancer cells in vitro: possible implications of cyclooxygenase-2 in cancer development. J. Clin. Gastroenterol., 27 (Suppl. 1): S47-S52, 1998.
36. Siglin, J. C., Barach, D. H., and Stoner, G. D. Effects of dietary isothiocyanate, ellagic acid, sulindac and calcium on the induction and progression of N-nitrosomethylbenzylamine-induced esophagcal carcinogenesis in rats. Carcinogenesis (Lond.), 16: 1101-1106, 1995.
37. Sawaoka, H., Kawano, S., Tsuji, S., Tsuji, M., Gunawan, E. S., Takei, Y., Nagano, K., and Hori, M. Cyclooxygenase-2 inhibitors suppress the growth of gastric cancer xenografts via induction of apoptosis in nude mice. Am. J. Physiol., 274 (6 Part 1): G1061-G1067, 1998.
38. Lehnert, T., Deschner, E. E., Karmali, R. A., and DeCosse, J. J. Effect of flurbiprofen and 16,16-dimethyl-prostaglandin E2 on gastrointestinal tumorigenesis induced by N-methyl-N′-nitro-N-nitrosoguanidine in rats. I. Squamous epithelium and mesenchymal tissue. J. Natl. Cancer Inst., 78: 923-929, 1987.
39. Lehnert, T., Deschner, E. E., Karmali, R. A., and DeCosse, J. J. Effect of flurbiprofen and 16,16-dimethyl-prostaglandin E2 on gastrointestinal tumorigenesis induced by N-methyl-N′-nitro-N-nitrosoguanidine in rats: glandular epithelium of stomach and duodenum. Cancer Res., 50: 381-384, 1990.
40. Goerttler, K., Edler, L., and Loehrke, H. Long term tumorigenicity of a single application of indomethacin or Amuno in adolescent and in adult male Sprague Dawley rats. Exp. Toxicol. Pathol., 44: 361-370, 1992.
41. Reis, L. A. G., Kosary, C. L., Hankey, B. F., Miller, B. A., and Edwards, B. K. (eds.). SEER Cancer Statistics Review, 1973-1995. Bethesda, MD: National Cancer Institute, 1998.